Assessment of Liver Cancer Response to TACE Using MultiHance-Enhanced MRI.

Completed · Not applicable

Conditions studied: Hepatocellular Carcinoma

In brief

This research is being done to find out if using the contrast agent MultiHance can be used to show how a liver tumor responds to the chemotherapy given during Transcatheter Arterial Chemoembolization (TACE).

Key facts

Study ID

NCT00539253

Run by

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

People needed

45

Starts

2007-09-01

Expected to finish

2013-12-01

Last updated by the study team

2017-09-26

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Outpatients between the ages of 18 - 80 seen in the cardiovascular and interventional radiology clinic who are scheduled for TACE.
• International Normalized Ratio (INR) <1.4
• Platelet count > 80,000

You may not qualify if…

• Contraindications to TACE procedure
• Unable to have an MRI Scan
• Allergy or hypersensitivity reactions to gadolinium or any other ingredients, including benzyl alcohol
• Patients with sickle cell anemia , hemoglobinopathies and other hemolytic anemias
• Known clinical hypersensitivity or a history of asthma or allergic respiratory disorders
• Patients with advanced renal failure (those currently requiring dialysis or with a Glomerular Filtration Rate<15cc/min)
• Pregnancy

Where it is running

• The Johns Hopkins Hospital — Baltimore, Maryland, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.